Consequências da COVID-19 em pacientes com obesidade
##plugins.themes.bootstrap3.article.sidebar##
Publicado
Apr 16, 2024
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Relacionar as consequências da COVID-19 com os achados das pesquisas realizadas em pacientes com obesidade que foram atingidos pela doença. Revisão bibliográfica: A literatura internacional sugere uma relação significativa entre a obesidade e a gravidade da COVID-19. A realização de investigações utilizando protocolos clínicos e epidemiológicos é crucial para estabelecer de forma mais precisa a conexão entre a obesidade e o risco de complicações da COVID-19. Essas pesquisas podem ajudar a obter uma compreensão mais aprofundada dessa associação e identificar os fatores subjacentes que contribuem para as complicações concomitantes em pacientes com sobrepeso. Considerações finais: A obesidade é uma doença crônica não transmissível, representando um fator de risco significativo para o agravamento da COVID-19. No entanto, é essencial ressaltar que ela é passível de prevenção. A adoção de hábitos saudáveis de vida não apenas pode mitigar os riscos associados à obesidade, mas também tem o potencial de reduzir a gravidade das infecções pela COVID-19, considerando que ambas são condições caracterizadas por processos inflamatórios.
##plugins.themes.bootstrap3.article.details##
Como Citar
NobreA. de A., PereiraM. J. V., & BarrosoW. A. (2024). Consequências da COVID-19 em pacientes com obesidade. Revista Eletrônica Acervo Saúde, 24(4), e14986. https://doi.org/10.25248/reas.e14986.2024
Seção
Revisão Bibliográfica
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
1. AMARAL LMB, et al. Vias metabólicas e hiperinflamação na COVID 19 em obesos diabéticos renais crônicos e sua reabilitação física pós-infecção / Metabolic pathways and hyperinflammation in COVID 19 in obese and chronic renal diabetic patients and their post-infection physical rehabilitation. Brazilian Journal of Development, 2021; 7: 67591-67615.
2. APOVIAN CM, et al. Body Weight Considerations in the Management of Type 2 Diabetes. Advances in therapy, 2019; 36(1): 44-58.
3. ATKINSON RL, et al. Human adenovirus-36 is associated with increased body weight and paradoxical reduction of serum lipids. Int J Obes, 2005; 29(9): 281-286.
4. BARROSO WA, et al. Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020; 14: 809-814.
5. BEZERRA et al. Factors associated with people’s behavior in social isolation during the covid-19 pandemic. Ciência e Saúde Coletiva, 2020; 25: 2411-2421.
6. BRANDÃO S, et al. Obesidade e risco de COVID-19: grave [livro eletrônico]. Recife, 2020; 1.
7. BURGOS-MORÓN E, et al. Relationship Between Oxidative Stress, ER Stress, and Inflammation in Type 2 Diabetes: The Battle Continues. J Clin Med, 2019; 9: 1385.
8. CAMPOS MR, et al. Carga de doença da COVID-19 e de suas complicações agudas e crônicas: reflexões sobre a mensuração (DALY) e perspectivas no Sistema Único de Saúde. Cadernos de Saúde Pública [online], 2020; 36: 11.
9. CARNETHON M. The Biggest Health Problem: Obesity. Sci Am, 2019; 1.
10. DANTZER, et al. Resilience and immunity. Brain BehavImmun, 2018; 74: 28-42.
11. DIETZ WSC. Obesity and its implications for COVID-19 mortality. Obesity (Silver Spring), 2020; 28(6): 1005.
12. DURÃES SA, et al. Implicações da pandemia da covid-19 nos hábitos alimentares. Revista Unimontes Científica, 2020; 22: 1-20.
13. GABBRIELLI R e PUGNO NM. The impact of mean body mass index on reported mortality from COVID-19 across 181 countries. Frontiers in public health, 2023; 11: 1106313.
14. GALLEGO P, et al. Adults with congenital heart disease during the coronavirus disease 2019 (COVID-19) pandemic: are they at risk? Revista, 2020; 73(10): 795-798.
15. GUO W, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev, 2020; 31: 3319.
16. HONCE RSS. Impact of obesity on influenza a virus pathogenesis, immune response, and evolution. Front Immunol, 2019; 10: 1071.
17. KALLIGEROS M, et al. Association of obesity with disease severity among patients with coronavirus disease 2019. Obesity (Silver Spring), 2020; 28(7): 1200-4.
18. KIRWAN R, et al. Sarcopenia During Covid-19 Lockdown Restritions: Long-Term Health Effects of Short-Term Muscle Loss. Geroscience, 2020; 42(6): 1547-1578.
19. KRAUSE M, et al. Coronavirus infection (SARS-CoV-2) in obesity and diabetes comorbidities: is heat shock response determinant for the disease complications? Diabetol Metab Syndr, 2020; 16: 12-63.
20. LIM S, et al. Proper Management of People With Obesity During the COVID-19 Pandemic. J. Obes. Metab. Syndr, 2020; 29(2): 84-98.
21. LUZI L e RADAELLE MG. Influenza and obesity: its odd relationship and the lessonsfor COVID-19 pandemic. Acta Diabetol, 2020; 57(6): 759-764.
22. MCMICHAEL TM, et al. Public Health–Seattle and King County, EvergreenHealth, and CDC COVID-19 Investigation Team. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. N Engl J Med, 2020; 382(21): 11.
23. MICHALAKIS K e ILIAS I. SARS-CoV-2 infection and obesity: common inflammatory and metabolic aspects. Diabetes Metab Syndr, 2020; 14(4): 69-71.
24. NASI, et al. The role of physical activity in individuals with cardiovascular risk factors: an opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport. J Cardiovasc, 2019; 20(10): 631-639.
25. OLIVEIRA ML, et al. Direct healthcare cost of obesity in Brazil: An application of the cost-of-illness method from the perspective of the public health system in 2011. PLoS One, 2015; 10: 4.
26. OLIVEROS, et al. The concept of normal weight obesity. Prog Cardiovasc Dis, 2014; 56(4): 426-433.
27. OXLEY TJ, et al. Large-vessel stroke as apresenting feature of Covid-19 in the young. NEngl J Med, 2020; 382: 60.
28. PECANHA, et al. Social isolation during the COVID-19 pandemic can increase physical inactivity and the global burden of cardiovascular disease. Am J Physiol Circ Physiol, 2020; 318(6): 1441-1446.
29. RYAN PM e CAPLICE NM. Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in coronavirus disease 2019? Obesity (Silver Spring), 2020; 28(7): 1191-1194.
30. SALES-PERES SHC, et al. Coronavirus (SARS-CoV-2) and the risk of obesity for critically illness and ICU admitted: Meta-analysis of the epidemiological evidence. Obes Res Clin Pract [online], 2020; 14: 389-397.
31. SBCBM Sociedade Brasileira de Cirurgia Bariátrica e Metabólica. Obesidade atinge mais de 6,7 milhões de pessoas no Brasil em 2022. SISVAN, 2023; 1-3.
32. SILVA GM, et al. Obesidade como fator agravante da COVID-19 em adultos hospitalizados: revisão integrativa. Acta Paulista de Enfermagem, 2021; 34.
33. SONZA, et al. Brazil before and during covid-19 pandemic: Impact on the practice and habits of physical exercise. Acta Biomed, 2021; 92(1):1-10.
34. STEFAN N, et al. Global pandemics interconnected – obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol, 2021; 1.
35. TANG, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost, 2020; 18(4): 844-847.
36. WORLD HEALTH ORGANIZATION (WHO). Coronavirus disease (COVID-19) Situation Report Region. Data as received by WHO from national authorities by 10:00 CEST, 15 set 2023. Geneva: WHO; 2023; 1.
37. WU D, et al. Plasma metabolomic and lipidomic alterations associated with COVID-19. Med Rxiv, 2020; 26.
38. ZHANG C, et al. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol, 2020; 5: 428-30.
2. APOVIAN CM, et al. Body Weight Considerations in the Management of Type 2 Diabetes. Advances in therapy, 2019; 36(1): 44-58.
3. ATKINSON RL, et al. Human adenovirus-36 is associated with increased body weight and paradoxical reduction of serum lipids. Int J Obes, 2005; 29(9): 281-286.
4. BARROSO WA, et al. Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020; 14: 809-814.
5. BEZERRA et al. Factors associated with people’s behavior in social isolation during the covid-19 pandemic. Ciência e Saúde Coletiva, 2020; 25: 2411-2421.
6. BRANDÃO S, et al. Obesidade e risco de COVID-19: grave [livro eletrônico]. Recife, 2020; 1.
7. BURGOS-MORÓN E, et al. Relationship Between Oxidative Stress, ER Stress, and Inflammation in Type 2 Diabetes: The Battle Continues. J Clin Med, 2019; 9: 1385.
8. CAMPOS MR, et al. Carga de doença da COVID-19 e de suas complicações agudas e crônicas: reflexões sobre a mensuração (DALY) e perspectivas no Sistema Único de Saúde. Cadernos de Saúde Pública [online], 2020; 36: 11.
9. CARNETHON M. The Biggest Health Problem: Obesity. Sci Am, 2019; 1.
10. DANTZER, et al. Resilience and immunity. Brain BehavImmun, 2018; 74: 28-42.
11. DIETZ WSC. Obesity and its implications for COVID-19 mortality. Obesity (Silver Spring), 2020; 28(6): 1005.
12. DURÃES SA, et al. Implicações da pandemia da covid-19 nos hábitos alimentares. Revista Unimontes Científica, 2020; 22: 1-20.
13. GABBRIELLI R e PUGNO NM. The impact of mean body mass index on reported mortality from COVID-19 across 181 countries. Frontiers in public health, 2023; 11: 1106313.
14. GALLEGO P, et al. Adults with congenital heart disease during the coronavirus disease 2019 (COVID-19) pandemic: are they at risk? Revista, 2020; 73(10): 795-798.
15. GUO W, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev, 2020; 31: 3319.
16. HONCE RSS. Impact of obesity on influenza a virus pathogenesis, immune response, and evolution. Front Immunol, 2019; 10: 1071.
17. KALLIGEROS M, et al. Association of obesity with disease severity among patients with coronavirus disease 2019. Obesity (Silver Spring), 2020; 28(7): 1200-4.
18. KIRWAN R, et al. Sarcopenia During Covid-19 Lockdown Restritions: Long-Term Health Effects of Short-Term Muscle Loss. Geroscience, 2020; 42(6): 1547-1578.
19. KRAUSE M, et al. Coronavirus infection (SARS-CoV-2) in obesity and diabetes comorbidities: is heat shock response determinant for the disease complications? Diabetol Metab Syndr, 2020; 16: 12-63.
20. LIM S, et al. Proper Management of People With Obesity During the COVID-19 Pandemic. J. Obes. Metab. Syndr, 2020; 29(2): 84-98.
21. LUZI L e RADAELLE MG. Influenza and obesity: its odd relationship and the lessonsfor COVID-19 pandemic. Acta Diabetol, 2020; 57(6): 759-764.
22. MCMICHAEL TM, et al. Public Health–Seattle and King County, EvergreenHealth, and CDC COVID-19 Investigation Team. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. N Engl J Med, 2020; 382(21): 11.
23. MICHALAKIS K e ILIAS I. SARS-CoV-2 infection and obesity: common inflammatory and metabolic aspects. Diabetes Metab Syndr, 2020; 14(4): 69-71.
24. NASI, et al. The role of physical activity in individuals with cardiovascular risk factors: an opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport. J Cardiovasc, 2019; 20(10): 631-639.
25. OLIVEIRA ML, et al. Direct healthcare cost of obesity in Brazil: An application of the cost-of-illness method from the perspective of the public health system in 2011. PLoS One, 2015; 10: 4.
26. OLIVEROS, et al. The concept of normal weight obesity. Prog Cardiovasc Dis, 2014; 56(4): 426-433.
27. OXLEY TJ, et al. Large-vessel stroke as apresenting feature of Covid-19 in the young. NEngl J Med, 2020; 382: 60.
28. PECANHA, et al. Social isolation during the COVID-19 pandemic can increase physical inactivity and the global burden of cardiovascular disease. Am J Physiol Circ Physiol, 2020; 318(6): 1441-1446.
29. RYAN PM e CAPLICE NM. Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in coronavirus disease 2019? Obesity (Silver Spring), 2020; 28(7): 1191-1194.
30. SALES-PERES SHC, et al. Coronavirus (SARS-CoV-2) and the risk of obesity for critically illness and ICU admitted: Meta-analysis of the epidemiological evidence. Obes Res Clin Pract [online], 2020; 14: 389-397.
31. SBCBM Sociedade Brasileira de Cirurgia Bariátrica e Metabólica. Obesidade atinge mais de 6,7 milhões de pessoas no Brasil em 2022. SISVAN, 2023; 1-3.
32. SILVA GM, et al. Obesidade como fator agravante da COVID-19 em adultos hospitalizados: revisão integrativa. Acta Paulista de Enfermagem, 2021; 34.
33. SONZA, et al. Brazil before and during covid-19 pandemic: Impact on the practice and habits of physical exercise. Acta Biomed, 2021; 92(1):1-10.
34. STEFAN N, et al. Global pandemics interconnected – obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol, 2021; 1.
35. TANG, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost, 2020; 18(4): 844-847.
36. WORLD HEALTH ORGANIZATION (WHO). Coronavirus disease (COVID-19) Situation Report Region. Data as received by WHO from national authorities by 10:00 CEST, 15 set 2023. Geneva: WHO; 2023; 1.
37. WU D, et al. Plasma metabolomic and lipidomic alterations associated with COVID-19. Med Rxiv, 2020; 26.
38. ZHANG C, et al. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol, 2020; 5: 428-30.